15.12.2020 HAEMATO AG  DE000A289VV1

DGAP-Adhoc: HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG


 

DGAP-Ad-hoc: HAEMATO AG / Key word(s): Takeover/Capital Increase
HAEMATO AG: HAEMATO AG acquires 'M1 Aesthetics GmbH' from M1 Kliniken AG - Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

15-Dec-2020 / 15:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Berlin, 15.12.2020 - M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind. For this purpose, the Management Board of HAEMATO AG decided today with the approval of the Supervisory Board to increase the company's share capital by EUR 2,467,201 to EUR 4,753,916 by issuing 2,467,201 new shares of HAEMATO AG through a capital increase against contribution in kind under exclusion of the subscription right of the shareholders by using the existing authorised capital. The new shares will be subscribed and taken over exclusively by M1 Kliniken AG. The transaction will be implemented with effect from 1.1.2021. After completion of the transaction, M1 Kliniken AG will hold a total of 75.8% of the share capital of HAEMATO AG.

M1 Aesthetics GmbH was valued on the basis of an IDW-S1 expert opinion with an enterprise value of a good € 58 million. The new HAEMATO shares were issued at a reference price of €23.55 per share, which corresponds to the volume-weighted average price of HAEMATO AG in the Xetra trading system in the period from 27.11.2020 to 9.12.2020.

In 2019 M1 Aesthetics GmbH reported sales of about 51 million Euro and an EBIT of almost 7 million Euro. For 2020, M1 Aesthetics GmbH is expecting sales of a good EUR 30 million and an EBIT of approximately EUR 4 million - also due to corona effects, among other things. A further increase in earnings is expected in the coming years.

About the HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company. The business activities focus on the growth markets of high-priced special pharmaceuticals. The focus is on therapies for cancer, HIV and other chronic diseases.

HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange.
Key figures of the HAEMATO AG share:

Subscribed capital: EUR 2,286,715
Listed class of shares: ordinary bearer shares
ISIN: DE000A289VV1
WKN: A289VV
Ticker symbol: HAEK




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]

15-Dec-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: [email protected]
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1155321

 
End of Announcement DGAP News Service

1155321  15-Dec-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1155321&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 289,86 274,12 197,84 238,33 285,04 248,14 282,00
EBITDA1,2 11,27 9,96 1,90 3,31 12,64 9,66 12,40
EBITDA-Marge3 3,89 3,63 0,96 1,39 4,43 3,89
EBIT1,4 9,42 8,50 -18,68 1,63 11,16 8,30 11,40
EBIT-Marge5 3,25 3,10 -9,44 0,68 3,92 3,35 4,04
Jahresüberschuss1 6,98 6,28 -1,17 -4,83 6,53 8,19 6,90
Netto-Marge6 2,41 2,29 -0,59 -2,03 2,29 3,30 2,45
Cashflow1,7 -8,35 0,56 -2,76 14,67 14,05 19,73 0,00
Ergebnis je Aktie8 3,20 2,70 -0,50 -1,02 1,35 1,57 1,34
Dividende8 3,00 1,00 0,00 0,00 1,10 1,20 3,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Harry Haseloff

INVESTOR-INFORMATIONEN
©boersengefluester.de
Haemato
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A289VV 16,700 - 87,33
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
10,44 15,54 0,67 8,40
KBV KCV KUV EV/EBITDA
0,61 4,43 0,35 6,85
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,20 0,70 4,19 18.07.2023
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
31.05.2023 31.08.2023 16.11.2023 17.05.2023
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-28,37% -26,14% -38,15% -9,24%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HAEMATO AG  ISIN: DE000A289VV1 können Sie bei EQS abrufen


Gesundheit , A289VV , HAEK , XETR:HAEK